USA - NASDAQ:RVLP - IE00BF2HDL56 - Common Stock
RVLP gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. RVLP may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, RVLP is valued expensive at the moment.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -79.93% | ||
| ROE | -418.14% | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 74.73% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -11.7 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.38 | ||
| Quick Ratio | 0.36 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.0282
-0.01 (-32.05%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.09 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.19 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -79.93% | ||
| ROE | -418.14% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 74.73% | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 804.97% | ||
| Cap/Sales | 8.33% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.38 | ||
| Quick Ratio | 0.36 | ||
| Altman-Z | -11.7 |
ChartMill assigns a fundamental rating of 2 / 10 to RVLP.
ChartMill assigns a valuation rating of 1 / 10 to RVL PHARMACEUTICALS PLC (RVLP). This can be considered as Overvalued.
RVL PHARMACEUTICALS PLC (RVLP) has a profitability rating of 2 / 10.
The Earnings per Share (EPS) of RVL PHARMACEUTICALS PLC (RVLP) is expected to grow by 27.9% in the next year.